$JAZZ just recorded an 11-point jump in its ACCE composite score, moving from 67 to 78 out of 100. That's a meaningful single-step move — the kind that typically reflects a shift in more than one underlying subscore rather than noise in a single factor.
Looking at the current breakdown, the story is clear: Quality at 86 and Momentum at 97 are doing the heavy lifting. Growth (64) and Value (63) are solid but not the standouts here.
A score move of +11 points from 67 to 78 most likely reflects one or more of the following:
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
Momentum accelerating further. A Momentum subscore of 97 is near the ceiling. If price action, relative strength, or earnings revision trends improved materially in the latest data cycle, that alone can push the composite higher by several points.
Quality metrics holding or improving. With a Quality score of 86, $JAZZ already ranks well on fundamentals. An ROE of 22.1%, a net margin of 20.4%, and a FCF yield of 7.0% are the kind of numbers that keep quality scores elevated — and any improvement in earnings quality signals or balance sheet metrics could have nudged this subscore up.
Growth or Value catching up. Both sit in the low-60s, which leaves room to move. Revenue growth of +15.5% year-over-year is genuine, and a forward P/E of 10.8 against a trailing P/E of 17.9 suggests the market is pricing in earnings expansion. If the model registered that compression as improving value, even a modest Value subscore gain contributes meaningfully to the composite.
What it means
The 1-year return of +129.3% explains why Momentum is so high. $JAZZ has been one of the stronger performers in Healthcare over that window, and the ACCE model is reflecting that.
What makes the score move more interesting than a pure momentum story is the quality foundation underneath it. A net margin above 20%, strong earnings quality, and a FCF yield of 7.0% suggest the business is generating real cash — not just riding sentiment.
The 6-model fair value estimate sits at $574.28, implying +121.3% upside from the current price of $259.53. That's a wide gap, and it's the kind of figure that warrants scrutiny rather than blind acceptance. Fair value models can diverge sharply from market prices for legitimate reasons — patent cliffs, pipeline risk, or sector-wide re-rating. But the analyst consensus target of $277.95 is more modest and still sits above the current price, suggesting external coverage also sees some room.
The Q3 FY2026 earnings result was essentially in line — a miss of -0.0% is a rounding event, not a red flag.
A score of 78 puts $JAZZ in solid territory on the ACCE composite. The combination of near-perfect Momentum and above-average Quality is what drove this move. Growth and Value scores have room to improve, and if they do, the composite has further to climb.
See the live score and full breakdown at acceinvestments.com/stocks/JAZZ.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
